Search - tctmd.com

Displaying 201 - 220 of 461

Sort: Relevancy | Date

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Conference News EAS 2019

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

Michael O'Riordan

June 03, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

News Daily News

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Yael L. Maxwell

April 18, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Daily News

Quality of CAD Care Varies by Type of Medicare Coverage

Todd Neale

February 20, 2019

News Daily News

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

Michael O'Riordan

February 08, 2019

News Daily News

Most Cardiovascular Drugs Can Be Safely Used in Pregnancy, Review Suggests

Todd Neale

February 01, 2019

News Daily News

Bias Over Knowledge: Whether Patients Get Guideline-Recommended Statins Depends on Physician Beliefs

Yael L. Maxwell

January 10, 2019

News Features

Top News in Clinical Cardiology: 2018

Yael L. Maxwell

December 28, 2018

News Features

Top News in Policy & Practice: 2018

Todd Neale

December 28, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

Shelley Wood

November 30, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Shelley Wood

November 11, 2018

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Daily News

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

Shelley Wood

October 29, 2018

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

Advertisement

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

CHD Mortality Significantly Elevated in Patients With Severe FH

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Quality of CAD Care Varies by Type of Medicare Coverage

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

Most Cardiovascular Drugs Can Be Safely Used in Pregnancy, Review Suggests

Bias Over Knowledge: Whether Patients Get Guideline-Recommended Statins Depends on Physician Beliefs

Top News in Clinical Cardiology: 2018

Top News in Policy & Practice: 2018

TCTMD’s Top 10 Most Popular Stories for November 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content